Health
Monoclonal antibodies can help high-risk people with COVID-19. But getting the drug to patients remains challe – The Philadelphia Inquirer
Demand for the drugs, which are the only approved treatment for high-risk patients who don’t need to be in the hospital, is lower than expected.
Back in December, the big worry about two newly approved treatments for early COVID-19 was that demand would far outstrip supply.
After all, some famous men had taken monoclonal antibodies after they were infected in the fall some of them before the drugs received emergency-use authorization and became highly visible converts.
Former President Donald Trump called a drug made by Regeneron a cure. (He was also given other treatments that may have helped him recover.) Ben Carson, former secretary of…
-
General10 hours agoThailand and Cambodia to hold negotiations in Malaysia over border conflict
-
General19 hours agoF1 live Belgian Grand Prix: Oscar Piastri starts second behind Lando Norris, wet race forecast for Spa-Francorchamps
-
General7 hours agoRelief as disability employment provider Bedford avoids administration
-
Noosa News7 hours ago‘Guard llama’ Larry killed in dog attack at hobby farm near Geraldton